best glp-1 drugs for weight loss usa 2025 Perspectives from employers on the costs and issues associated with covering agonists GLP-1 Drugs from the Gray

Trial data have shown decreases in serious cardiovascular complications, including cardiovascular mortality, nonlethal heart attacks, and nonfatal cerebrovascular accidents, among individuals with type 2 diabetes and pre-existing cardiovascular pathology or high cardiovascular risk [3,5,13,14,37]

Qualitative and quantitative data were both extracted

Limitations of Use Saxenda (liraglutide [rDNA origin] injection) is not indicated for the treatment of type 2 diabetes

ACHIEVE-4 (NCT05803421) This trial evaluates orforglipron in patients with type 2 diabetes already treated with basal insulin, assessing whether the addition of an oral GLP-1 agonist can improve glycemic control and reduce insulin requirements